Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request

This article was originally published in The Pink Sheet Daily

Executive Summary

UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.

You may also be interested in...



Just-Approved Cimzia Set To Enter Tough RA Market

UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.

Just-Approved Cimzia Set To Enter Tough RA Market

UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.

Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access

Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel